{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:29:48Z","timestamp":1761514188878,"version":"3.37.3"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"New South Wales Cardiovascular Research Network Research Development Project","award":["100715"],"award-info":[{"award-number":["100715"]}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","award":["RG134592"],"award-info":[{"award-number":["RG134592"]}],"id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian National Health and Medical Research Council Career Development Fellowship","award":["1122854"],"award-info":[{"award-number":["1122854"]}]},{"name":"MESA","award":["HHSN268201500003I","N01-HC-95159","N01-HC-95160","N01-HC-95161","N01-HC-95162","N01-HC-95163","N01-HC-95164","N01-HC-95165","N01-HC-95166","N01-HC-95167","N01-HC-95168","N01-HC-95169"],"award-info":[{"award-number":["HHSN268201500003I","N01-HC-95159","N01-HC-95160","N01-HC-95161","N01-HC-95162","N01-HC-95163","N01-HC-95164","N01-HC-95165","N01-HC-95166","N01-HC-95167","N01-HC-95168","N01-HC-95169"]}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["UL1-TR-000040","UL1-TR-001079","UL1-TR-001420"],"award-info":[{"award-number":["UL1-TR-000040","UL1-TR-001079","UL1-TR-001420"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1093\/ndt\/gfy120","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T07:09:40Z","timestamp":1523516980000},"page":"1009-1016","source":"Crossref","is-referenced-by-count":14,"title":["Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis"],"prefix":"10.1093","volume":"34","author":[{"given":"Sahapab","family":"Anuwatmatee","sequence":"first","affiliation":[{"name":"Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A","family":"Allison","sequence":"additional","affiliation":[{"name":"Department of Family and Preventive Medicine, University of California, San Diego, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Shlipak","sequence":"additional","affiliation":[{"name":"Kidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, San Francisco, CA, USA"},{"name":"Department of Medicine, San Francisco VA Medical Center, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn L","family":"McClelland","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Loyola University, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shudi","family":"Tang","sequence":"additional","affiliation":[{"name":"Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Hou","sequence":"additional","affiliation":[{"name":"Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry-Anne","family":"Rye","sequence":"additional","affiliation":[{"name":"Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-7614","authenticated-orcid":false,"given":"Kwok Leung","family":"Ong","sequence":"additional","affiliation":[{"name":"Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"2019060303552388200_gfy120-B1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"2019060303552388200_gfy120-B2","article-title":"Fibroblast growth factor 21 in chronic kidney disease","author":"Anuwatmatee","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2019060303552388200_gfy120-B3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"2019060303552388200_gfy120-B4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.atherosclerosis.2016.11.033","article-title":"The role of fibroblast growth factor 21 in atherosclerosis","volume":"257","author":"Kokkinos","year":"2017","journal-title":"Atherosclerosis"},{"key":"2019060303552388200_gfy120-B5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"2019060303552388200_gfy120-B6","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","article-title":"Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"key":"2019060303552388200_gfy120-B7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"2019060303552388200_gfy120-B8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","article-title":"Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity","volume":"71","author":"Mraz","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019060303552388200_gfy120-B9","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"2019060303552388200_gfy120-B10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"key":"2019060303552388200_gfy120-B11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J Hepatol"},{"key":"2019060303552388200_gfy120-B12","doi-asserted-by":"crossref","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","article-title":"Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile","volume":"5","author":"Lin","year":"2010","journal-title":"PLoS One"},{"key":"2019060303552388200_gfy120-B13","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"2019060303552388200_gfy120-B14","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00125-015-3652-2","article-title":"Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"key":"2019060303552388200_gfy120-B15","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1210\/jc.2014-3465","article-title":"Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria","volume":"100","author":"Lee","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2019060303552388200_gfy120-B16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2215\/CJN.06450611","article-title":"Racial differences in the incidence of chronic kidney disease","volume":"7","author":"Muntner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019060303552388200_gfy120-B17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-ethnic study of atherosclerosis: objectives and design","volume":"156","author":"Bild","year":"2002","journal-title":"Am J Epidemiol"},{"key":"2019060303552388200_gfy120-B18","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1210\/jc.2012-2267","article-title":"Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes","volume":"97","author":"Ong","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2019060303552388200_gfy120-B19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00125-014-3458-7","article-title":"The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"key":"2019060303552388200_gfy120-B20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2019060303552388200_gfy120-B21","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.2215\/CJN.02450314","article-title":"Cumulative systolic BP and changes in urine albumin-to-creatinine ratios in nondiabetic participants of the multi-ethnic study of atherosclerosis","volume":"9","author":"Zemaitis","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019060303552388200_gfy120-B22","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1681\/ASN.2009050546","article-title":"Rapid decline of kidney function increases cardiovascular risk in the elderly","volume":"20","author":"Shlipak","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2019060303552388200_gfy120-B23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2215\/CJN.01230212","article-title":"Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis","volume":"7","author":"Park","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019060303552388200_gfy120-B24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/aje\/kwn350","article-title":"The association between physical activity and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis","volume":"169","author":"Bertoni","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2019060303552388200_gfy120-B25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"2019060303552388200_gfy120-B26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijcard.2011.11.034","article-title":"Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: results from a multi-ethnic cohort","volume":"166","author":"Veeranna","year":"2013","journal-title":"Int J Cardiol"},{"key":"2019060303552388200_gfy120-B27","first-page":"1","article-title":"Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"2019060303552388200_gfy120-B28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.biopha.2017.06.100","article-title":"Fibroblast growth factor 21 ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway","volume":"93","author":"Li","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2019060303552388200_gfy120-B29","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1210\/en.2012-2276","article-title":"Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db\/db mice","volume":"154","author":"Kim","year":"2013","journal-title":"Endocrinology"},{"key":"2019060303552388200_gfy120-B30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/dc08-1054","article-title":"Serum levels of the adipokine FGF21 depend on renal function","volume":"32","author":"Stein","year":"2009","journal-title":"Diabetes Care"},{"key":"2019060303552388200_gfy120-B31","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.metabol.2010.03.018","article-title":"Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis","volume":"59","author":"Han","year":"2010","journal-title":"Metab Clin Exp"},{"key":"2019060303552388200_gfy120-B32","doi-asserted-by":"crossref","first-page":"e18398","DOI":"10.1371\/journal.pone.0018398","article-title":"Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/6\/1009\/28750744\/gfy120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T03:56:18Z","timestamp":1559534178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/6\/1009\/4996300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,5,15]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy120","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"type":"print","value":"0931-0509"},{"type":"electronic","value":"1460-2385"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2018,5,15]]}}}